Zydus Life Gets USFDA Nod for Heart Failure Drug

Zydus Lifesciences announced on Wednesday, July 10, that it has received final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and valsartan tablets.

Key Takeaways from Zydus Lifesciences

• Zydus Lifesciences said on Wednesday that it had gained final FDA permission to commercialise Sacubitril and Valsartan tablets.
• The combination of medicines is used to treat chronic heart failure in adults, lowering the risk of mortality and hospitalisation.
• The medicine will be produced at the group's formulation manufacturing plant in Moraiya, Ahmedabad (India).

Sacubitril and Valsartan are used to treat chronic heart failure in adults, helping to minimise the risk of mortality and hospitalisation. The aforementioned medicine is equivalent to the reference specified drug, Entresto tablets.

The medicine will be made at the group's formulation manufacturing plant in Moraiya, Ahmedabad (India), according to the company.

Since the filing process began in fiscal year 2003-04, the group has received 399 approvals and submitted over 460 ANDAs.

The pharma company posted a consolidated net profit of Rs 1,182.3 crore in Q4 FY24, which was much higher than the Rs 296.6 crore recorded in Q4 FY23. Revenue from operations increased 10.44% to Rs 5,533.8 crore during the quarter, compared to Rs 5,010.6 crore in the same quarter the previous year.

About Zydus Lifesciences Limited

Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), a major Indian pharmaceutical corporation, is a fully integrated global healthcare provider. With extensive domain understanding in healthcare, it possesses significant capabilities across the pharmaceutical value chain. Zydus has acquired a reputation among Indian pharmaceutical businesses for delivering comprehensive and full healthcare solutions, including formulations, active pharmaceutical ingredients, animal healthcare products, and wellness goods. One of Zydus' distinguishing traits is its extensive history and ancestry. The corporation originated in the 1950s. Mr. Ramanbhai B. Patel (late) launched the firm in 1952, as a first-generation entrepreneur and doyen in the area of Indian pharmaceuticals.
 

Cadila Healthcare was created in 1995 as a result of the organisation's restructuring under the Zydus group. From a humble revenue of Rs 250 crores in 1995, the group saw considerable financial development, reaching a turnover of more than Rs 19,500 crores in FY24.
 

Zydus continues to develop with an unwavering commitment to meet unmet healthcare needs, remaining true to its brand promise of being devoted to life in all its aspects. Simultaneously, it commits to its purpose of promoting healthier, happier communities across the world.

Read More About Zydus Lifesciences Share Price Here!